Last week, direct-to-consumer health companies Noom and Hims & Hers both launched new ventures in the rapidly growing peptide market. Noom’s new OpenRx brand will initially offer four products including sermorelin, a peptide that is often prescribed for muscle support. Hims introduced Peptides+, which also offers sermorelin along with four other products. The new initiatives follow recent actions by the U.S. Department of Health and Human Services (HHS) to loosen regulatory policy on compounding peptides.
In July, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to evaluate a list of peptide bulk drug substances for possible inclusion on the Section 503A Bulks List, including BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. The 503A Bulks List identifies which bulk drug substances may be used by traditional compounding pharmacies and licensed physicians when preparing patient-specific medications. The peptides discussed are associated with a variety of proposed uses, including opioid withdrawal, insomnia, narcolepsy, cerebral ischemia, migraine, and trigeminal neuralgia.
PCAC voted to recommend six substances for potential inclusion on the 503A Bulks List, but these votes were only advisory. The FDA is not bound by the committee’s recommendations, and none of the peptides are currently FDA-approved or included on the 503A Bulks List. Before any of these substances could become eligible for routine Section 503A compounding, the FDA would need to accept the recommendations and complete the formal rulemaking process. However, on October 30, HHS announced the availability of a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” permitting licensed pharmacies to compound certain peptides under specific conditions while rulemaking continues. HHS’s stance makes clear that further changes in the direct-to-consumer peptide arena are on the way.
Sign up to receive Rivkin Rounds at www.RivkinRounds.com.
Recent Comments